Imara: No benefit in interim sickle cell trial results

 Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population

Interim results in Forte trial for beta-thalassemia demonstrated no meaningful benefit in transfusion burden or improvement in most disease-related biomarkers

Tovinontrine was generally well-tolerated across studies

Both Phase 2b clinical trials and further development of tovinontrine in sickle cell and beta-thalassemia to be discontinued

https://finance.yahoo.com/news/imara-announces-results-interim-analyses-104500846.html